Other therapies

Keiji Iwatsuki, Naohito Hatta, Nagwa M. Elwan, Selma Ugurel, Lauren L. Lockwood, Jürgen C. Becker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prognostic factors for Langerhans cell histiocytosis (LCH) or class I histiocytosis may include: (1) the number of organs involved, (2) the severity of organ failure, and (3) the age of the patients. Complications such as hemophagocytic syndrome and thrombocytopenia also affect the prognosis [1-4]. In general, younger patients with widely disseminated disease and organ dysfunction have a high risk of mortality. In a series of 101 children with LCH [2], the overall survival rate was 79% at 1 year, 74% at 3 years, and 71% at 5 years; however, in patients with liver or spleen involvement, 1-year survival was 33% and 5-year survival was only 25%. In adult LCH [3], the probability of survival 5 years post diagnosis was 92.3% overall: 100% for patients with single-system disease, 87.8% for isolated pulmonary disease, and 91.7% for multisystem disease.

Original languageEnglish
Title of host publicationSkin Cancer - A World-Wide Perspective
PublisherSpringer Berlin Heidelberg
Pages355-369
Number of pages15
ISBN (Print)9783642050718
DOIs
Publication statusPublished - Dec 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Iwatsuki, K., Hatta, N., Elwan, N. M., Ugurel, S., Lockwood, L. L., & Becker, J. C. (2011). Other therapies. In Skin Cancer - A World-Wide Perspective (pp. 355-369). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-05072-5_25